Compass Therapeutics Provides Corporate Update
Compass Therapeutics, Inc. (CMPX) reported a business update, including progress in clinical trials for CTX-009 in biliary tract and colorectal cancer, positive clinical activity in the Phase 1b study of CTX-471, and FDA acceptance of the CTX-8371 IND. The company also announced a CEO succession plan and ended 2023 with an estimated $152 million in cash and marketable securities, providing cash runway into mid-year 2026.
The clinical progress of CTX-009 and CTX-471 represents a significant stride in oncology, particularly for patients with advanced biliary tract cancer (BTC) and small cell lung cancer (SCLC). The bispecific antibody CTX-009, targeting DLL4 and VEGF-A, could potentially offer a novel therapeutic approach for BTC, a cancer with limited treatment options. The reported complete response in SCLC from CTX-471 treatment is noteworthy, as SCLC is known for its aggressive nature and poor prognosis. The observed overall response rate (ORR) of 27% in advanced melanoma patients treated with CTX-471 is promising, given the historical context where melanomas can be resistant to certain therapies. These developments may lead to improved patient outcomes and could potentially shift the treatment paradigm if the efficacy is confirmed in larger trials.
Compass Therapeutics' report on the advancement of their clinical trials is a critical indicator for investors assessing the company's pipeline potential. The extension of patient enrollment and the expected timelines for top-line data release are pivotal for financial forecasting. The cash position of $152 million, providing a runway into mid-year 2026, is a strong indicator of the company's financial health and ability to sustain operations through crucial trial phases. However, the market will be closely monitoring the results of the ongoing trials, as positive outcomes could significantly enhance the company's valuation, while any setbacks could pose risks to investor returns.
The oncology sector is highly competitive, with numerous companies vying for a share of the market. Compass Therapeutics' progress in their clinical trials positions them within a niche segment of the market focused on advanced cancers with high unmet medical needs. The potential market impact of CTX-009 and CTX-471, if approved, could be substantial, given the current demand for more effective cancer treatments. The company's strategic focus on advancing their pipeline reflects an understanding of the market's demand for innovation in oncology therapeutics. Their ability to reach key clinical milestones may influence their competitive standing and could attract partnership opportunities or acquisition interest from larger pharmaceutical entities.
01/05/2024 - 08:00 AM
We continue to open clinical sites and enroll patients in COMPANION-002, the Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC). Consistent with prior guidance, top line data from this study continue to be expected in the second half of 2024. Enrollment of patients in COMPANION-003, the Phase 2 study of CTX-009 in patients with advanced colorectal cancer (CRC), has been extended into the first quarter of 2024. We expect to report top-line data from this study by mid-year 2024. Further evidence of clinical activity has been observed in the Phase 1b, monotherapy study of CTX-471. First, one patient with small cell lung cancer with a previously reported partial response has converted to a complete response, as confirmed by a PET scan, while continuing therapy on CTX-471. Second, in addition to the four responses previously reported, a new partial response has been observed in a patient with advanced melanoma, bringing the overall response rate (ORR) in patients with advanced melanoma in this study to 27% (3 of 11). Following FDA acceptance of the CTX-8371 IND in late 2023, we expect to dose the first patient in 1Q 2024. As previously disclosed, effective January 9, 2024, Vered Bisker-Leib, PhD, Compass President and COO, will lead Compass as Compass Chief Executive Officer and join the Compass board of directors. Effective January 9, 2024, Thomas Schuetz, MD, PhD, Compass’ Scientific Founder and Chief Executive Officer will transition to President of Research and Development and be appointed Vice Chair of the Compass board of directors. Ended 2023 with an estimated $152 million in cash and marketable securities, which is expected to provide cash runway for the company into mid-year 2026. BOSTON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported a business update.
“We made significant progress in the fourth quarter of the year across our portfolio, and we look forward to reporting top-line data from COMPANION-003 by mid-year and COMPANION-002 in the second half of the year. We are also excited to report additional responses in our Phase 1b monotherapy study of CTX-471, including a complete response in a patient with small cell lung cancer. We hope to see additional efficacy signals in the second part of our Phase 1b study, where we are studying CTX-471 in combination with KEYTRUDA® in patients with melanoma, NSCLC and SCLC,” said Vered Bisker-Leib, PhD, incoming Chief Executive Officer of Compass.
“We are excited to have Vered Bisker-Leib elevated to the Chief Executive Officer role recognizing many years of strong performance. We are equally pleased that our founding CEO, Thomas Schuetz, will continue to play a key role at the Company,” said Carl Gordon, PhD, Chair of Compass’ Board.
Development Pipeline Updates:
CTX-009 (DLL4 and VEGF-A bispecific antibody)
We continue to enroll patients in COMPANION-002, a U.S. Phase 2/3 study of CTX-009 in combination with Paclitaxel in BTC. This randomized Phase 2/3 study is designed to enroll 150 patients with BTC who have received one prior systemic therapy. The primary endpoint of the study is overall response rate (ORR), and secondary endpoints include progression free survival (PFS), overall survival (OS), clinical benefit rate (CBR) and duration of response (DOR). Enrollment is expected to be completed by mid-year 2024; top line data are expected from this study in the second half of 2024. Enrollment of patients in COMPANION-003, a U.S. Phase 2 study of CTX-009 as a monotherapy in patients with advanced, metastatic CRC, has been extended to first quarter 2024. The study design is an Adaptive Simon Two-Stage, with Stage 1 of the study enrolling 37 patients; if 3 or more responses are confirmed in Stage 1, the study will advance to Stage 2, and an additional 47 patients will be enrolled. The study is enrolling patients with CRC who have received two or three prior systemic therapies irrespective of their KRAS mutation status. Patients are being evaluated for safety and tolerability, as well as clinical response. We expect to report top-line data from this study by mid-year 2024. CTX-471 (CD137 agonist)
CTX-471 is a CD137 agonistic antibody, which binds to a unique epitope of the co-stimulatory molecule 4-1BB with an optimized affinity. We continue to dose and follow patients in the Phase 1b monotherapy study of CTX-471 where five responses have been observed, all in patients who previously received checkpoint blocker(s). A durable PR in a patient with SCLC has converted to a CR, as confirmed by a PET scan. Additionally, a new PR in a patient with advanced melanoma, was observed, leading to an ORR in the subset of patients with advanced melanoma of 27% (3 of 11). The fifth response occurred in a patient with mesothelioma. Phase 1b combination arm of CTX-471 and Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with select solid tumors is ongoing. The dose-escalation portion of the study has been fully enrolled and enrollment in the dose expansion cohorts has begun. In the expansion cohort, we plan on enrolling 60 patients with melanoma, NSCLC and SCLC, who will be randomized into two doses. CTX-8371 (PD-1 x PD-L1 bispecific antibody)
CTX-8371 is a next generation bispecific checkpoint inhibitor that simultaneously targets PD-1 and PD-L1 and exhibits a unique mechanism-of-action that involves cleavage of cell surface PD-1. Following the FDA acceptance of the IND for CTX-8371, the first patient is expected to be dosed in the Phase 1 clinical trial in the first quarter of 2024. Corporate Highlights:
The Company’s CEO succession plan is effective as of January 9, 2024, with the elevation of Vered Bisker-Leib, PhD, to Chief Executive Officer and her addition to the Compass board of directors. Thomas Schuetz, MD, PhD, Compass’ Scientific Founder and current Chief Executive Officer will transition to President of Research and Development and assume the role of Vice Chair of the Compass board of directors. About Compass Therapeutics https://www.compasstherapeutics.com .
Forward-Looking Statements This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to Compass’s financial position to continue advancing its product candidates, expectations about cash runway, business and development plans, and statements regarding Compass’s product candidates, including their development and clinical trial milestones such as the expected trial design, timing of enrollment, patient dosing and data readouts, regulatory plans with respect to Compass’s product candidates and the therapeutic potential thereof. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, Compass’s ability to raise the additional funding it will need to continue to pursue its business and product development plans, the inherent uncertainties associated with developing product candidates and operating as a development stage company, Compass’s ability to identify additional product candidates for development, Compass’s ability to develop, complete clinical trials for, obtain approvals for and commercialize any of its product candidates, competition in the industry in which Compass operates and market conditions. These forward-looking statements are made as of the date of this press release, and Compass assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents Compass files with the U.S. Securities and Exchange Commission (SEC) available at www.sec.gov, including without limitation Compass’s latest Annual Report on Form 10-K, Quarterly Report on Form 10-Q and subsequent filings with the SEC.
Investor Contact ir@compasstherapeutics.com
Media Contact media@compasstherapeutics.com
What is the latest business update from Compass Therapeutics, Inc. (CMPX)?
Compass Therapeutics, Inc. (CMPX) reported progress in clinical trials for CTX-009 in biliary tract and colorectal cancer, positive clinical activity in the Phase 1b study of CTX-471, and FDA acceptance of the CTX-8371 IND. The company also announced a CEO succession plan and ended 2023 with an estimated $152 million in cash and marketable securities.
What are the key developments in the CTX-009 clinical trials for biliary tract and colorectal cancer?
Compass Therapeutics, Inc. (CMPX) continues to open clinical sites and enroll patients in COMPANION-002, the Phase 2/3 randomized study of CTX-009 in patients with advanced biliary tract cancer. Enrollment of patients in COMPANION-003, the Phase 2 study of CTX-009 in patients with advanced colorectal cancer, has been extended. Top-line data from these studies are expected by mid-year and the second half of 2024, respectively.
What clinical activity has been observed in the Phase 1b study of CTX-471?
Positive clinical activity has been observed in the Phase 1b, monotherapy study of CTX-471, including a complete response in a patient with small cell lung cancer and a new partial response in a patient with advanced melanoma. First, one patient with small cell lung cancer with a previously reported partial response has converted to a complete response, as confirmed by a PET scan, while continuing therapy on CTX-471. Second, in addition to the four responses previously reported, a new partial response has been observed in a patient with advanced melanoma, bringing the overall response rate (ORR) in patients with advanced melanoma in this study to 27% (3 of 11).
What is the status of the CTX-8371 clinical trial?
Following the FDA acceptance of the CTX-8371 IND, the first patient is expected to be dosed in the Phase 1 clinical trial in the first quarter of 2024.
What is the CEO succession plan for Compass Therapeutics, Inc. (CMPX)?
Effective January 9, 2024, Vered Bisker-Leib, PhD, Compass President and COO, will lead Compass as Compass Chief Executive Officer and join the Compass board of directors. Thomas Schuetz, MD, PhD, Compass’ Scientific Founder and Chief Executive Officer will transition to President of Research and Development and be appointed Vice Chair of the Compass board of directors.
What is the financial position of Compass Therapeutics, Inc. (CMPX)?
Compass Therapeutics, Inc. (CMPX) ended 2023 with an estimated $152 million in cash and marketable securities, providing cash runway for the company into mid-year 2026.
